Valuation: Mabion S.A.

Market Cap 121M 32.21M 28M 26.06M 23.93M 45.19M 3.07B 45.89M 307M 1.53B 121M 118M 5.13B P/E 2024
-22.7x
P/E 2025 -1.8x
Enterprise Value 127M 33.9M 29.47M 27.43M 25.18M 47.55M 3.24B 48.29M 323M 1.61B 127M 125M 5.4B EV / Sales 2024
1,574,345x
EV / Sales 2025 7,560,388x
Free-Float
67.18%
Yield 2024 *
-
Yield 2025 -
1 day+0.54%
1 week+1.22%
1 month+0.81%
3 months-0.13%
6 months-9.47%
Current year+6.88%
1 week 7.27
Extreme 7.27
7.54
1 month 7.16
Extreme 7.16
7.96
Current year 7.01
Extreme 7.01
10
1 year 6.7
Extreme 6.7
10
3 years 6.7
Extreme 6.7
23.6
5 years 6.7
Extreme 6.7
110
10 years 6.7
Extreme 6.7
139
Manager TitleAgeSince
Chief Executive Officer - -
Corporate Officer/Principal - -
Corporate Officer/Principal - -
Director TitleAgeSince
Chairman 60 2021-05-12
Director/Board Member 53 -
Director/Board Member - 2021-02-22
Change 5-day change 1-year change 3-year change Capi.($)
+0.54%+1.22%-22.85%-57.49% 32.21M
+2.35%+2.74%+38.10%+74.02% 56.54B
-0.21%-7.38%+27.52%+63.59% 53.6B
-2.44%+1.40%-15.61%-13.72% 22.91B
-2.85%-7.78%-9.28%+352.92% 21.37B
-0.31%-0.21%+23.57%-14.93% 20.27B
+0.79%-1.06%+33.99%-30.63% 17.56B
-2.23%-8.39%+16.38%+545.71% 14.75B
+3.41%-6.61%+162.81%+287.77% 13.53B
-5.25%-4.23%+42.32%+160.72% 13.33B
Average -0.68%-3.29%+29.70%+136.80% 23.39B
Weighted average by Cap. -0.23%-2.96%+30.60%+119.99%

Financials

2024 2025
Net sales 69.02 18.44 16.03 14.92 13.7 25.87 1.76K 26.27 175.86 876.28 69.25 67.73 2.94K 15.76 4.21 3.66 3.41 3.13 5.91 401.84 6 40.15 200.05 15.81 15.46 670.81
Net income -6.33M -1.69M -1.47M -1.37M -1.26M -2.37M -162M -2.41M -16.14M -80.42M -6.35M -6.22M -270M -62.61M -16.73M -14.54M -13.53M -12.43M -23.47M -1.6B -23.83M -160M -795M -62.82M -61.44M -2.67B
Net Debt -35.18M -9.4M -8.17M -7.61M -6.98M -13.19M -897M -13.39M -89.65M -447M -35.3M -34.53M -1.5B 6.32M 1.69M 1.47M 1.37M 1.25M 2.37M 161M 2.4M 16.09M 80.19M 6.34M 6.2M 269M
Logo Mabion S.A.
Mabion SA is a Poland-based biopharmaceutical company. The Company provides a broad spectrum of services in the segment of small and medium-sized projects at various stages of development (from early-stage discovery to commercial manufacturing). The Company's competencies include the selection of protein expression technologies, their purification, GMP-standard manufacturing activities (obtaining Active Substances - Drug Substance and Finished Products - Drug Product), development of analytical tools (for structural, functional, physicochemical characterization), clinical development, clinical analytics and a full range of regulatory activities in the development and operational areas. The Company's goal is to establish itself as a recognizable player in the global contract manufacturing and contract drug development market and to complete its full transformation into an integrated biologics CDMO company.
Employees
202
Date Price Change Volume
26-07-31 PLN 7.460 +0.54% 13,281
26-07-30 PLN 7.420 -.--% 7,641
26-07-29 PLN 7.420 +0.27% 14,384
26-07-28 PLN 7.400 +0.54% 13,352
26-07-27 PLN 7.360 -0.14% 5,516

Quarterly revenue - Rate of surprise